DE-ESCALATE Intermittent Androgen Deprivation Therapy in the Era of Androgen Receptor Pathway Inhibitors; a Phase 3 Pragmatic Randomised Trial
- Coordinator
- Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer Aisbl, Belgium
- Runs
- 1 June 2023 to 31 May 2028
- Status
- Running
- EU funding
- €7.2m
- Total cost
- €7.2m
- Partners
- 6 organisations in 5 countries
- Type
- Research and Innovation Action
- Grant agreement
- 101104574
What the project is doing
In the project's own words, from its summary on CORDIS.
Prostate Cancer is the most common cancer in European men. Despite dramatic improvements in early diagnostic and local treatment, one out of five prostate cancer patients will die from their disease. Despite progress in the past years, it remains critical to improve on the present strategy for advanced and metastatic prostate cancer. Within the proposed project, we will evaluate whether intermittent intensified androgen deprivation treatment (iADT) in metastatic prostate cancer is not inferior to continuous treatment in terms of oncological benefit while minimizing side effects and resource utilization and improving patient quality of life.
The proposed clinical trial is designed to detect early if iADT has a negative impact on overall survival compared to continuous therapy. If successful, the outcomes of the project will define a new evidence-based standard of care for metastatic hormone sensitive prostate cancer. The proposed research could lead to improved patient survival and quality of life but also improve health system sustainability. This is a multidisciplinary and multistakeholder consortium involving clinical oncologists, surgeons, health economists and patient representatives.
The study design was successfully discussed with patients. This action is part of the Cancer Mission cluster of projects on ‘Diagnosis and treatment’.
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Organisation Europeenne Pour La Recherche Et Le Traitement Du Cancer Aisbl | Bruxelles / Brussel | Belgium | Coordinator |
| Europa Uomo | Antwerpen | Belgium | Participant |
| Grupo Espanol De Tratamiento De Tumores Urologicos Asociacion | Madrid | Spain | Participant |
| Unicancer | Paris | France | Participant |
| Syreon Kutato Intezet Korlatolt Felelossegu Tarsasag | Budapest | Hungary | Participant |
| Cancer Trials Ireland Company Limited by Guarantee | Dublin | Ireland | Participant |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI